- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04145986
Evaluation of Prognostic Monitoring for Young Breast Cancer Patients
November 14, 2019 updated by: Na Shi, Peking Union Medical College Hospital
Evaluation of Prognostic Monitoring for Young Breast Cancer Patients Via Analysis of Immunoinflammation-related Protein Complexes in Blood
The relationship between immune inflammation-related protein complexes in blood and recurrence or metastasis of breast cancer with completed standard treatment for young ladies will be studied.
Study Overview
Status
Recruiting
Conditions
Detailed Description
200 patients younger than 35 with breast cancer will be followed up.
Peripheral venous blood was collected every 3 to 6 months.
Change regularity of breast cancer-specific immune inflammation-related protein complexes in blood at different follow-up time points will be studied.
The relationship between disease specific protein complexes and pathological state of patients will be analyzed.
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Na Shi
- Phone Number: +86-13910571604
- Email: 1836935573@qq.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100005
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Na Shi
- Phone Number: +86-13910571604
- Email: 1836935573@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 35 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Breast cancer patients with ages equal 35 or below.
Description
Inclusion Criteria:
- Female
- invasive breast cancer patients confirmed by postoperative pathology after surgery for breast lump
- Breast cancer-related chemotherapy and radiotherapy completed
- Young ladies with ages equal 35 or below
Exclusion Criteria:
- Male
- Aged above 35
- Breast Carcinoma in situ
- Women in pregnancy or breastfeeding
- Suffering from other malignant tumors
- Non-compliant patient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
young ladies
Young ladies≤ 35 years old.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
immune inflammation-related protein complexes
Time Frame: 2 years
|
The change of immune inflammation-related protein complexes which is measured by gel permeation chromatography.
|
2 years
|
blood markers
Time Frame: 2 years
|
The expression of CA153, CEA, CA125 in the blood of the patients, which are measured by electro-chemiluminescence immunoassay.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shi Na, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 25, 2019
Primary Completion (Anticipated)
March 1, 2020
Study Completion (Anticipated)
March 1, 2025
Study Registration Dates
First Submitted
October 29, 2019
First Submitted That Met QC Criteria
October 29, 2019
First Posted (Actual)
October 31, 2019
Study Record Updates
Last Update Posted (Actual)
November 18, 2019
Last Update Submitted That Met QC Criteria
November 14, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUMCH-BC503
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Institut fuer FrauengesundheitSamsung Bioepis Co., Ltd.RecruitingBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer FemaleGermany
-
Wake Forest University Health SciencesAtrium Health NavicentActive, not recruitingBreast Cancer Female | Early-stage Breast CancerUnited States
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany